News | BenevolentAI

Year

Type

Search

90 results found

BenevolentAI Appoints Kenneth Mulvany as Executive Chairman

BenevolentAI to present on explainable AI for drug discovery at BioTechX Europe 2024

Interim results for the six months ended 30 June 2024

Notice of Interim Results

How AI is transforming drug discovery

Appointment of Adviser

5._Investor_News_293x220.jpg

Leadership team change

BenevolentAI and AstraZeneca collaboration yields continued success as further novel target progressed into portfolio

BenevolentAI-Appoints-Dr.-Joerg-Moeller-as-Chief-Executive-Officer.jpg

BenevolentAI CEO to join panel at Morgan Stanley 3rd Annual Life Sciences AI Summit

BenevolentAI_to_present_at_41st_Annual_J.P._Morgan_Healthcare_Conference.jpg

BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference

BenevolentAI announces further success with AstraZeneca collaboration as novel Heart Failure target selected

Result of Annual General Meeting

5._Investor_News_293x220.jpg

BenevolentAI provides an update on its business priorities

Publication of the Revised Agenda for the 2024 AGM

Proposed changes to BenevolentAI's Board composition

BenevolentAI's Dr Anne Phelan discusses positive safety data from the Phase 1a clinical study BEN-8744

BenevolentAI announces positive topline safety and pharmacokinetic data from the Phase Ia clinical study of BEN-8744 in healthy volunteers

BenevolentAI appoints new Chief Technology Officer

Publication of 2023 Annual Report and 2024 AGM Notice

BenevolentAI Unaudited preliminary results for the year ended 31 December 2023

BenevolentAI CEO Dr Joerg Moeller discusses AI's impact on drug discovery

Notice of Preliminary Results

BenevolentAI-Appoints-Dr.-Joerg-Moeller-as-Chief-Executive-Officer.jpg

BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer

BenevolentAI_to_present_at_41st_Annual_J.P._Morgan_Healthcare_Conference.jpg

BenevolentAI to present at 42nd Annual J.P. Morgan Healthcare Conference

Interim results for the six months ended 30 June 2023

Directorate Change

BenevolentAI Signs Strategic Collaboration with Merck

BenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer

Notice_of_Interim_Results_and_Analyst___Investor_Event.jpg

Notice of Interim Results

Appointment of Catherine Isted, ACMA, as Chief Financial Officer

BenevolentAI doses first participants in clinical trial of BEN-8744; targets PDE10, an AI-derived novel target for the treatment of Ulcerative Colitis

BenevolentAI_progresses_BEN-34712_for_the_potential_treatment_of_ALS_into_IND-enabling_studies.jpg

BenevolentAI progresses BEN-34712 for the potential treatment of ALS into IND-enabling studies

New_preclinical_data_on_AI-generated_target_identified_in_BenevolentAI_and_AstraZeneca_collaboration_presented_at_ATS_2023.jpg

New preclinical data on AI-generated target identified in BenevolentAI and AstraZeneca collaboration presented at ATS 2023

BenevolentAI unveils strategic plan to position the Company for a new era in AI

9xchange joins forces with BenevolentAI to integrate its AI technology into its innovative biopharma marketplace

Result of Annual General Meeting

BenevolentAI announces top-line Phase IIa results for its topical pan-Trk inhibitor BEN-2293 (1%) in mild-to-moderate atopic dermatitis

BenevolentAI strengthens its Board of Directors with the appointment of digital innovation expert Marcello Damiani

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022

Notice of Preliminary Results

Cowen-43rd-Annual-Health-Care-Conference-W--Nick-Keher.jpg

BenevolentAI to present at the Cowen 43rd Annual Health Care Conference

The Secret Sauce To BenevolentAI’s Ongoing Success

BenevolentAI_Submits_CTA_For_BEN-8744_An_Oral_PDE10_Inhibitor_As_A_First-In-Class_Treatment_For_Ulcerative_Colitis.jpg

BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis

BenevolentAI_to_present_at_41st_Annual_J.P._Morgan_Healthcare_Conference.jpg

BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference

BenevolentAI_to_present_at_Jefferies_Investor_Conference_in_November.jpg

BenevolentAI To Present At Jefferies Investor Conference In November

BenevolentAI_achieves_further_milestones_in_AI-enabled_target_identification_collaboration_with_AstraZeneca.jpg

BenevolentAI Achieves Further Milestones In AI-Enabled Target Identification Collaboration With AstraZeneca

Analyst / Investor Event

Interim_results_for_the_six_months_ended_30_June_2022.jpg

Interim Results For The Six Months Ended 30 June 2022

Analyst / Investor Event And Interim Results

Notice_of_Interim_Results_and_Analyst___Investor_Event.jpg

Notice Of Interim Results And Analyst / Investor Event

BenevolentAI_appoints_GSK_drug_discovery_veteran_Dr_Nicola_Richmond_as_Vice_President_of_AI.jpg

BenevolentAI Appoints GSK Drug Discovery Veteran Dr Nicola Richmond As Vice President Of AI

BenevolentAI_announces_participation_in_upcoming_investor_conferences.jpg

BenevolentAI Announces Participation In Upcoming Investor Conferences

BenevolentAI Announces Board Changes

BenevolentAI_achieves_third_milestone_in_its_AI-enabled_drug_discovery_collaboration_with_AstraZeneca.jpg

BenevolentAI Achieves Third Milestone In Its AI-Enabled Drug Discovery Collaboration With AstraZeneca

BenevolentAI Begins Trading On Euronext Amsterdam

BenevolentAI_joins_the_World_Economic_Forums_Global_Innovators_Community.jpg

BenevolentAI Joins The World Economic Forum’s Global Innovators Community

DNDi_and_BenevolentAI_collaborate_to_accelerate_life-saving_drug_discovery_research_in_dengue.jpg

DNDi And BenevolentAI Collaborate To Accelerate Life-Saving Drug Discovery Research In Dengue

Will AI turbocharge the hunt for new drugs?

RECOVERY_trial_results_demonstrate_baricitinib_reduces_deaths_in_hospitalised_COVID-19_patients.jpg

RECOVERY Trial Results Demonstrate Baricitinib Reduces Deaths In Hospitalised COVID-19 Patients

BenevolentAI_partners_with_the_Helix_Group_at_Stanford_University_to_advance_research_on_AI-driven_drug_discovery.jpg

BenevolentAI Partners With The Helix Group At Stanford University To Advance Research On AI-Driven Drug Discovery

BenevolentAI_Appoints_Daniel_Neil_as_Chief_Technology_Officer.jpg

BenevolentAI Appoints Daniel Neil As Chief Technology Officer

BenevolentAI_announces_3-year_collaboration_expansion_with_AstraZeneca_focused_on_systemic_lupus_erythematosus_and_heart_failure.jpg

BenevolentAI Announces 3-Year Collaboration Expansion With AstraZeneca Focused On Systemic Lupus Erythematosus And Heart Failure

AstraZeneca doubles down on BenevolentAI drug hunting partnership, adding heart failure, lupus targets

BenevolentAI_to_Present_at_the_40th_Annual_JP_Morgan_Healthcare_Conference.jpg

BenevolentAI To Present At The 40th Annual JP Morgan Healthcare Conference

BenevolentAI_achieves_second_major_collaboration_milestone_with_novel_idiopathic_pulmonary_fibrosis_target_selected_for_AstraZenecas_portfolio.jpg

BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca’s Portfolio

BenevolentAI_identifies_novel_target_for_ulcerative_colitis_and_advances_candidate_to_IND_CTA-enabling_studies.jpg

BenevolentAI Identifies Novel Target For Ulcerative Colitis And Advances Candidate To IND/CTA-Enabling Studies

BenevolentAI_appoints_Dr_John_Orloff_to_its_Board_of_Directors.jpg

BenevolentAI Appoints Dr John Orloff To Its Board Of Directors

How tech is changing healthcare

BenevolentAI_announces_the_appointment_of_biopharma_luminary_Dr_Francois_Nader_as_Chairman.jpg

BenevolentAI Announces The Appointment Of Biopharma Luminary Dr François Nader As Chairman

Baricitinib_first_identified_by_BenevolentAI_as_a_COVID-19_treatment_is_granted_emergency_use_in_India_in_response_to_its_escalating_crisis.jpg

Baricitinib, First Identified By BenevolentAI As A COVID-19 Treatment, Is Granted Emergency Use In India In Response To Its Escalating Crisis

Data_from_Eli_Lillys_COV-BARRIER_trial_shows_baricitinib_reduced_deaths_in_hospitalised_COVID-19_patients_by_38_.jpg

Data From Eli Lilly’s COV-BARRIER Trial Shows Baricitinib Reduced Deaths In Hospitalised COVID-19 Patients By 38%

BenevolentAI_named_as_one_of_Fierce_Medtechs_Fierce_15_of_2020.jpg

BenevolentAI Named As One Of Fierce Medtech’s Fierce 15 Of 2020

BenevolentAI_announces_first_patient_dosed_in_its_Atopic_Dermatitis_clinical_trial.jpg

BenevolentAI Announces First Patient Dosed In Its Atopic Dermatitis Clinical Trial

BenevolentAI_and_AstraZeneca_achieve_collaboration_milestone_with_novel_AI-generated_chronic_kidney_disease_target.jpg

BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target

AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio

FDA_grants_Emergency_Use_Authorisation_for_baricitinib_in_hospitalised_COVID-19_patients_nine_months_after_initial_hypothesis_was_published_by_BenevolentAI.jpg

FDA Grants Emergency Use Authorisation For Baricitinib In Hospitalised COVID-19 Patients Nine Months After Initial Hypothesis Was Published By BenevolentAI

Sir_Nigel_Shadbolt_joins_BenevolentAI_as_a_non-executive_director.jpg

Sir Nigel Shadbolt joins BenevolentAI as a non-executive director

NIAID_Releases_Additional_Data_Validating_BenevolentAIs_Hypothesis_For_Baricitinib_As_A_Treatment_For_COVID-19_Patients_In_Large-Scale_Randomised_Control_Trial.jpg

NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial

BenevolentAI_welcomes_Professor_Russ_Altman_as_scientific_advisor.jpg

BenevolentAI Welcomes Professor Russ Altman As Scientific Advisor

BenevolentAIs_platform-derived_hypothesis_for_COVID-19_treatment_validated_in_US_NIAID_randomised_control_trial.jpg

BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial

Clinical_data_validates_BenevolentAI_s_AI_predicted_hypothesis_for_baricitinib_as_a_potential_treatment_for_COVID-19.jpg

Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19

COVID-19 And AI: An Editorial Review In EMBO From Michael B. Schultz, Daniel Vera, David A. Sinclair

Potential_Treatment_For_COVID-19_Identified_By_BenevolentAI_Enters_Randomised_Clinical_Trial.jpeg

Potential treatment for COVID-19 identified by BenevolentAI enters randomised clinical trial

MIT Technology Review names BenevolentAI as a top 10 breakthrough tech

BenevolentAI-announces-scientific-collaboration-with-UC-San-Diego-to-investigate-Cerebral-Cavernous-Malformations.jpg

BenevolentAI announces scientific collaboration with UC San Diego to investigate Cerebral Cavernous Malformations

BenevolentAI_Announces_90_Million_Investment_From_Temasek.jpeg

BenevolentAI announces $90 million investment from Temasek

BenevolentAI_Announces_Agreement_With_Leading_Healthcare_Company_To_Leverage_BenevolentAIs_Technology_Platform.jpeg

BenevolentAI announces agreement with leading healthcare company to leverage BenevolentAI’s technology platform

Neuropore_Therapies_And_BenevolentAI_Enter_Strategic_Collaboration_To_Discover_Novel_Therapeutics_Through_The_Application_Of_Artificial_Intelligence.jpeg

Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence

AstraZeneca_starts_artificial_intelligence_collaboration_to_accelerate_drug_discovery.jpg

AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery

Sign up for our news

News-and-Media-Press Kit.jpg

See our library of resources